- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01285388
Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Volunteers
25. juni 2018 oppdatert av: Yungjin Pharm. Co., Ltd.
A Dose Double-blind,Placebo-controlled,Single Dosing,Dose-escalation Clinical Trial to Investigate the Safety,Tolerability and Pharmacokinetic Characteristics of MB12066 in Healthy Male Subjects
The purpose of this study is to investigate the safety and tolerability of MB12066 after a single oral dose and to investigate the pharmacokinetic characteristics of MB12066 after a single oral dose.
Studieoversikt
Detaljert beskrivelse
Safety/ Tolerability evaluation
-Adverse events, Physical examinations, Vital signs, ECG (including continuous ECG monitoring), Laboratory tests (including hematology, chemistry, coagulation, PBS, NAD(P)+/NAD(P)H ratio, urinalysis), CIC
Pharmacokinetic Evaluation
- Serial blood samples and urine collections for pharmacokinetic evaluations will be conducted between 0 (pre-dose) and 96 hours after a single oral dose.
- Blood sampling time pre-dose, 1h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h, 72h post-dose
- Urine collection time 0h - 6h, 6h - 12h, 12h - 24h, 24h - 48h, 48h - 72h
- Evaluation parameters AUClast, AUCinf, Cmax, Tmax, t1/2, Vd/F, CL/F, Ae, fe, CLR
Studietype
Intervensjonell
Registrering (Faktiske)
50
Fase
- Fase 1
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
20 år til 45 år (Voksen)
Tar imot friske frivillige
Ja
Kjønn som er kvalifisert for studier
Mann
Beskrivelse
Inclusion Criteria:
- Subject is informed of the investigational nature of this study and voluntarily agrees to participate in this study and signs an Institutional Review Board (IRB) - approved informed consent prior to performing any of the screening procedures
- Healthy Korean male volunteers, age ranged 20 to 45 years (both inclusive)
- A subject with body weight between 60 kg (inclusive) and 90 kg (exclusive) and body mass index (BMI) between 18.5 (inclusive) and 25 (exclusive). ☞ BMI (kg/m2) = weight (kg) / {height (m)}2
- Findings within the range of clinical acceptability in medical history and physical examination, and laboratory results within the laboratory reference ranges for the relevant laboratory tests (unless the investigator considers the deviation to be irrelevant for the purpose of the study)
Exclusion Criteria:
- A subject with history of allergies including drug allergies (aspirin, antibiotics, etc.), or history of clinically significant allergies
- A subject with clinical evidence or history of hepatic (including carrier of hepatitis virus), renal, respiratory, endocrine, neurologic, immunologic, hematologic, oncologic, psychiatric, or cardiovascular disease
- A subject with history of gastrointestinal disease or surgery (except simple appendectomy or repair of hernia), which can influence the absorption of the study drug
- A subject whose hemoglobin(Hb) level < 12 g/dL
- A subject with fasting plasma glucose (FPG) level ≤ 70 mg/dL or ≥ 126 mg/dL
- A subject with HbA1c level ≥ 7.0 mmol/L
- A subject whose systolic blood pressure (SBP) ≤ 90 mmHg or ≥ 140 mmHg, diastolic blood pressure (DBP) ≤ 40 mmHg or ≥ 90 mmHg or pulse rate (PR) ≥ 100 /min after at least 5 min sitting
- A subject with history of drug abuse or positive urine drug screening test
- A subject who has taken any prescribed medication or herbal compounds within 14 days prior to the study drug administration. In addition, a subject who has taken any over-the-counter drug or vitamin supplements within 7 days prior to the study drug administration (However, investigators can judge the subject, who has taken the medications during those periods above, eligible for the trial if all other conditions are satisfied.)
- A subject who has participated in any other clinical trial either for investigational or marketed drugs within 8 weeks before the study drug administration
- A subject who has donated or had loss of ≥ 400 mL of blood within 8 weeks prior to start of administration of study drug
- A subject who consumes more than 21 units of alcohol per week or unable to stop drinking throughout the study period.
- A smoker (except for whom quitted smoking prior to the drug administration for at least 3 months)
- A subject who heavily takes caffeine or caffeine-containing products, grapefruit, grapefruit juice, grapefruit-containing products
- A subject with unusual dietary habit
- A subject who was previously assigned to treatment during this study
- The investigator judges the subject not eligible for the study after reviewing clinical laboratory results or other reasons.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Screening
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Placebo komparator: placebo
|
MB12066 10mg, 100mg/tab.
once oral dose MB12066 10, 30, 100, 150, 200mg
Andre navn:
|
|
Eksperimentell: MB12066 10mg
|
MB12066 10mg, 100mg/tab.
once oral dose MB12066 10, 30, 100, 150, 200mg
Andre navn:
|
|
Aktiv komparator: MB12066 30mg
|
MB12066 10mg, 100mg/tab.
once oral dose MB12066 10, 30, 100, 150, 200mg
Andre navn:
|
|
Aktiv komparator: MB12066 100mg
|
MB12066 10mg, 100mg/tab.
once oral dose MB12066 10, 30, 100, 150, 200mg
Andre navn:
|
|
Aktiv komparator: MB12066 150mg
|
MB12066 10mg, 100mg/tab.
once oral dose MB12066 10, 30, 100, 150, 200mg
Andre navn:
|
|
Aktiv komparator: MB12066 200mg
|
MB12066 10mg, 100mg/tab.
once oral dose MB12066 10, 30, 100, 150, 200mg
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Safety/ Tolerability evaluation
Tidsramme: from day-1 to day8-10
|
Adverse events, Physical examinations, Vital signs, ECG (including continuous ECG monitoring), Laboratory tests (including hematology, chemistry, coagulation, PBS, NAD(P)+/NAD(P)H ratio, urinalysis), CIC
|
from day-1 to day8-10
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Pharmacokinetic Evaluation
Tidsramme: between 0 (pre-dose) and 96 hours after a single oral dose.
|
|
between 0 (pre-dose) and 96 hours after a single oral dose.
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Kyung-Sang Yu, Professor, Clinical Research Institute of Seoul National University Hospital
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. juli 2010
Primær fullføring (Faktiske)
1. januar 2011
Studiet fullført (Faktiske)
1. januar 2011
Datoer for studieregistrering
Først innsendt
4. juli 2010
Først innsendt som oppfylte QC-kriteriene
26. januar 2011
Først lagt ut (Anslag)
28. januar 2011
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
27. juni 2018
Siste oppdatering sendt inn som oppfylte QC-kriteriene
25. juni 2018
Sist bekreftet
1. juni 2018
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- MB12066_001
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .